Pharmaceutical blister pack

Sustainable Pharma Packaging Starts with Asking Better Questions

We were delighted to see AstraZeneca and Deloitte nominated for an MCA Award for their work on sustainable pharmaceutical packaging.

Cambridge Design Partnership supported the project through our materials science and manufacturing teams. It is a strong example of what we see with large pharmaceutical clients: sustainable packaging is a product development challenge, not a side issue about greener materials.

The project focused on moving towards fully recyclable blister packaging. Three requirements shaped the work: recyclability, barrier performance and ease of manufacture, all in a regulated market where drug performance and patient safety matter.

That combination shows why pharmaceutical packaging forces us to ask better questions.

 

A greener material can still be the wrong answer

The narrow question is, “Can we make this pack recyclable?”

The better question is, “What has to be true for a more sustainable pack to work in the real world?”

That moves clients from material preference to product evidence.

A material cannot be judged by its specification alone, or by whether it is recyclable, bio-based, fiber-based or lower carbon. It has to protect the medicine, run on packaging lines, survive transport and storage, meet regulatory expectations, support credible claims and work in the waste and recycling systems where it is sold.

Sustainable pharma packaging is not a material swap. It is a system design challenge.

 

Supplier data is not product evidence

The narrow question is, “Is this material more sustainable?”

The better question is, “Will this material still protect the medicine after we process it, seal it, pack it and ship it?”

A supplier may present a laminate, film, coating or fiber-based structure with strong barrier data, valid and given in good faith. But it usually describes the material under laboratory test conditions, not after forming, sealing, printing, sterilization, filling, transit and storage.

Once a material enters a commercial process, barrier performance can fall, seals can become inconsistent, moisture protection can become marginal, and machinability can create scrap.

The supplier is describing the material. The development team has to prove the pack.

 

The current pack may be over-specified

Patient safety is not negotiable. But that does not mean the current pack should always be copied.

The narrow question is, “Can the new pack match the existing pack?”

The better question is, “What pack performance does this medicine actually need?”

With over 25 years working with leading pharmaceutical companies, you soon learn that packs are often based on specifications set years ago. Some requirements are essential. Others may reflect old material choices, equipment limits, qualification decisions or requirements that have not been reviewed for a long time.

There is also a practical reason legacy formats stay in place. Changing a pharmaceutical pack can create cost, project risk and, in some cases, the need for regulatory approval or updated filings. That risk is real. But it is also why the requirement needs to be clear before change is ruled in or out.

That does not mean organizations should lower standards. It means defining the real requirement: barrier performance, shelf life, safety margins, sterility and sustainability all needs to be considered and understood.

 

Not every sustainability opportunity is worth pursuing

In many of our projects, the useful starting point is not one problem material. It is the portfolio.

The narrow question is, “Which material should we replace?”

The better question is, “Which change is worth pursuing?”

Which formats create the most material burden? Which markets create the greatest regulatory exposure? Which SKUs use more packaging than the protection need justifies? Which changes affect validation or line performance? Which products should be left alone because the benefit is too small or the risk is too high?

That portfolio view matters because the cost of change is real. Packaging lines are optimized, validated and expensive to alter. Changing equipment, requalifying a process or updating a specification can take months if notyears and require major investment.

A material that cannot run at line speed is not a solution. A pack that improves end-of-life performance but creates stability or validation risk is not a solution.

 

Recyclable in theory is not enough

The narrow question is, “Is this pack recyclable?”

The better question is, “Will this pack actually be collected, sorted and recycled in the market where it is sold?”

For global brands, a pack may be recyclable in one country, misunderstood in another and incinerated in a third. It may need separation steps patients will not perform, or use coatings, adhesives, inks, labels or mixed components that reduce the value of the recovered stream. It may be too small, contaminated, complex or unfamiliar for the sorting system.

Designing for end-of-life means working backwards from real infrastructure: patient behavior, local collection, sorting, recycler tolerance and the actual route in each market.

If that chain breaks, the intended environmental benefit may never appear.

 

Waiting for regulation is already too late

The EU Packaging and Packaging Waste Regulation is moving packaging towards clearer requirements for recyclability, labeling, waste management and evidence. Healthcare and contact-sensitive packaging has specific treatment because patient protection matters. But that should not be read as permission to wait.

Pharmaceutical packaging changes can take years. If a change affects barrier properties, stability, sterility, line performance or regulatory filings, the timescale expands quickly.

The narrow question is, “What does regulation require next year?”

The better question is, “What packaging choices are we making now that will still be in market when regulation, infrastructure and procurement expectations have moved on?”

 

Leadership starts with the better question

It’s great to see this our Astra Zeneca and Deloitte collaboration project recognized with a nomination but it is equally important to recognize that the best consultancy projects begin with the client challenge. Real progress starts when companies identify the challenges that need solving and ask the right questions. AstraZeneca has consistently done that on sustainability, creating the impetus for work like this and driving the search for practical solutions.

This work on blister packs is just one element of AstraZeneca’s wider sustainability program. The company has set a goal of 50% waste circularity by 2030 and is already applying circular thinking across the business: from liquid helium reuse to silica waste reduction and its Turbuhaler take-back scheme in Sweden.

That is leadership in pharmaceutical sustainability.

At the heart of CDP’s approach: how to turn sustainability ambition into real products.

Connect with CDP

For more on how to accelerate meaningful innovation in sustainable pharmaceutical packaging, contact Cambridge Design Partnership.

From Pilot to Portfolio: Scaling Circular Packaging

We have seen plenty of circular packaging pilots that work in isolation.

A new design that’s more recyclable. An increase in recycled content. A workable deposit return trial that performs well in-store. A positive refill system experiment with a strong story behind it.

Then they stall

Not because the intent was wrong, but because pilots sit outside the full operating system and true commercial pressures. They are rightly protected from the cost, infrastructure, and commercial realities to test and learn consumer behavior, but are often ill-equipped to adapt for scale.

That is why packaging Extended Producer Responsibility (EPR) matters, as this is a scale-centric challenge.

It shifts packaging from a waste topic to a design and business topic. The Organisation for Economic Co-operation and Development (OECD), describes EPR as a policy approach that makes producers responsible through the post-consumer stage, while also generating funding and information for collection, sorting, and recycling systems. And the policy context is no longer theoretical. In the EU, the PPWR entered into force on February 11, 2025, and generally applies from August 12, 2026. In the UK, obligated producers must register, report packaging data, and pay fees. Australia is reforming packaging regulation to align packaging with circular economy principles. Ontario completed its transition to full producer responsibility on January 1, 2026. Canada expects packaging EPR for packaging in most, if not all, provinces and territories by 2030.

So the question is no longer whether circular packaging should be scaled.

The more useful question is this: will compliance effort be treated as a cost of doing business, or used as a lens for sharper portfolio choices?

Because as EPR becomes a reality, companies are forced to define things that pilots can leave vague or don’t answer. Which end-of-life pathway is realistic in each market? How likely is collection and effective sorting in normal conditions? Where is packaging complexity creating cost without improving recovery? Those are not paperwork questions. They are design questions, procurement questions, and portfolio questions. This is why EPR is better understood as a portfolio lens than a pilot trigger. Pilots still matter. They are often essential for testing formats, claims, and consumer participation models. But pilots alone do not tell you how a portfolio performs across geographies, channels, suppliers, materials, and recovery systems. That wider view is where scale is won or lost.

Pilots often succeed because they benefit from exceptional conditions. One geography. One retail partner. One highly engaged consumer group. One supplier willing to stretch. One team willing to intervene when reality gets messy. In some cases, even supportive national policy environments, such as France’s emerging regulatory push on reuse and refill under its circular economy legislation, can effectively act as a scaled, semi-controlled test bed.

Portfolios operate under normal conditions. They carry multiple markets, multiple channels, multiple suppliers, competing cost pressures, and uneven infrastructure. At that scale, the test is not whether a packaging idea worked once. The test is whether it still works when it becomes business as usual.

EPR also brings consumer behavior into focus. Packaging systems only work when people can participate in them. If organizations say they are consumer-centered, this is where that claim has to show up. Legislation should be used not just to meet regulatory requirements, but to design packaging experiences that are intuitive, low-friction, and aligned with everyday behavior. Disposal instructions need to be clear. Return and refill participation needs to feel intuitive. Sorting needs to work in ordinary households, not just in ideal conditions. Get this right, and you improve more than recovery. You reduce contamination, lower fee exposure, and strengthen the overall product experience.  Regulations will then not only encourage circularity, but they create a purposeful moment of action and innovation for companies to strengthen brand trust, delivering tangible value to consumers as well as the business. In other words, EPR can turn circularity from a pilot activity into an operating model that also improves the consumers’ experience, if companies use the opportunity.

Circularity has always been a system design challenge, and EPR is accelerating this advancement. The task is not simply to improve one pack in isolation. It is to understand how material choice, format, infrastructure compatibility, consumer participation, evidence burden, fee exposure, and end market reality interact. That is a different level of discipline, and it tends to expose weaknesses quickly.

A portfolio view allows better questions. Which formats create the highest compliance and cost exposure? Which packs have the weakest real-world recovery pathway? Which material choices add complexity without improving the outcome? Where can harmonization reduce cost and improve recyclability? Which claims are robust, and which are vulnerable? Where could redesign create both environmental gain and economic value?

The strongest companies will not treat EPR as a layer of administration added to yesterday’s packaging choices. They will use it to redesign how those choices are made. In practice, that means defining end-of-life pathways in operational terms, separating what can be standardized globally from what must be adapted locally, evaluating packs with a balanced scorecard rather than a single metric, testing behavior honestly, building the evidence plan early, and staging change across the portfolio where learning is fastest and risk is lowest.

Handled tactically, EPR will bring short-term pain with few long-term gains. Handled strategically, it should shape and accelerate the decisions you ultimately need to make to protect your future.

As part of a strategy, it can become a source of commercial advantage. Not because regulation is inherently beneficial to producers. It is not. But because it can force the level of scrutiny, many organizations have postponed. That scrutiny can lead to fewer problematic formats, better alignment between design and infrastructure, lower material intensity, stronger claims, smarter use of recycled content, and clearer investment cases for reuse, refill, or redesign where those moves are genuinely viable.

The companies most likely to create value from packaging EPR will be the ones that use that pressure to review the portfolio properly and scale the changes that actually work.

At Cambridge Design Partnership, we help teams translate regulatory changes to practical design and engineering action. That means identifying where recovery pathways are weak, where behavioral assumptions are unrealistic, where evidence requirements need to shape the brief earlier, and where material and format decisions are creating hidden risk. Typically, that means combining circular diagnostic work, sustainability screening, Sustainability Clean sheeting, human-centered design, engineering validation, and regulatory readiness into a single decision process.

It’s worth asking one final question. Are you only preparing to comply, or are you using this moment to reshape the portfolio for a more circular and commercially resilient future?